Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit

Allergy. 2023 May;78(5):1369-1371. doi: 10.1111/all.15620. Epub 2022 Dec 21.
No abstract available

Publication types

  • Letter

MeSH terms

  • Angioedemas, Hereditary* / drug therapy
  • Angioedemas, Hereditary* / prevention & control
  • Antibodies, Monoclonal, Humanized
  • Complement C1 Inhibitor Protein / therapeutic use
  • Humans
  • Plasma Kallikrein
  • United Kingdom / epidemiology

Substances

  • lanadelumab
  • Antibodies, Monoclonal, Humanized
  • Plasma Kallikrein
  • Complement C1 Inhibitor Protein